Company intelligence / Profile preview

NmVac4-A

New Brunswick, New Jersey, United States

Ownership: Private
Employees: ~130000
Development stage: Other

Overview

JnJ Innovative Medicine, formerly known as Janssen, is a leading global pharmaceutical company and a division of Johnson & Johnson. The company is currently developing NmVac4-A, a quadrivalent meningococcal conjugate vaccine designed to protect against Neisseria meningitidis serogroups A, C, W-135, and Y. This program is part of a broader effort to expand their vaccine portfolio and address global public health needs in infectious diseases. The vaccine candidate is currently in late-stage clinical development, specifically targeting populations in regions with high disease burden such as the African meningitis belt.

Therapeutic areas: Infectious Diseases
Modalities: VaccineRecombinant proteinGlycoconjugate vaccine
Industry: Pharma

Partnerships

PATHSerum Institute of India

Beyond the preview

Go deeper on NmVac4-A.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NmVac4-A.

Explore the full profile